Beta Drugs Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 35.1% CAGR over last 5 years
- Company has a healthy return on capital (ROCE) of 30.6%
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
- Latest quarter profit grew 1724.9% YoY, showing strong momentum
- Company has delivered good sales growth of 31.9% CAGR over last 5 years
- Company has consistently been profitable over the last 5 years
CONS
- Promoter holding has decreased over last 2 years: -7.6pp
- Total debt has risen sharply - up 838.5% year on year
- Working capital days have increased from 115 to 230 days
- Stock is trading at 9.8x its book value
- Operating margins have contracted to 20.6% from 23.6%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.80 | 37.69 | 455825.66 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9305.00 | 84.45 | 247018.51 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4913.00 | 85.68 | 186874.73 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1155.00 | 25.53 | 115211.69 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1395.95 | 33.46 | 112773.00 | 0.93 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1868.25 | 92.32 | 100943.83 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2105.00 | 17.41 | 96254.46 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2322.05 | 46.95 | 95911.14 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| DRREDDY | 1145.00 | 29.66 | 95570.85 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1658.00 | 25.70 | 95397.65 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2462.00 | 38.65 | 69483.71 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BETA | 2123.90 | 56.94 | 2362.04 | 0.00 | 164.86 | 1724.88 | 1255.50 | 1239.00 | 25.23 | 21.80 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| 88 | 94 | 100 | 87 | 94 | 126 | |
| 70 | 76 | 88 | 70 | 76 | 105 | |
| Operating Profit | 18 | 17 | 13 | 17 | 18 | 20 |
| OPM % | 20.90% | 18.49% | 12.63% | 19.47% | 18.81% | 16.30% |
| -1 | 2 | 3 | 2 | 3 | 2 | |
| Interest | 2 | 3 | 3 | 4 | 4 | 3 |
| Depreciation | 3 | 4 | 4 | 4 | 5 | 4 |
| Profit before Tax | 12 | 12 | 16 | 10 | 12 | 22 |
| Tax % | 25.17% | 26.17% | 25.23% | 18.72% | 23.50% | 25.21% |
| Net Profit | 0 | 0 | 12 | 9 | 9 | 16 |
| 9.31 | 9.40 | 11.59 | 8.40 | 8.93 | 14.78 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 407 | |
| 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 339 | |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 68 |
| OPM % | 18.70% | 17.91% | 19.72% | 21.31% | 23.23% | 23.39% | 20.29% | 20.59% | 16.66% |
| 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 10 | |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 14 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 17 |
| Profit before Tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 60 |
| Tax % | 1.05% | -1.69% | 21.36% | 26.50% | 27.62% | 25.18% | 25.26% | 25.54% | 23.74% |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 46 |
| EPS | 0.00 | 0.00 | 0.00 | 12.20 | 25.82 | 31.95 | 37.90 | 42.02 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 32%
- 3 Years:
- 25%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 35%
- 3 Years:
- 20%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- 43%
- 3 Years:
- 29%
- 1 Year:
- 12%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 26%
- 3 Years:
- 26%
- Last Year:
- 24%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| 24 | 32 | 47 | 59 | 83 | 113 | 148 | 187 | |
| 9 | 23 | 26 | 22 | 24 | 24 | 20 | 140 | |
| Trade Payables | 6 | 13 | 14 | 20 | 32 | 40 | 59 | 71 |
| 2 | 7 | 11 | 9 | 15 | 17 | 26 | 37 | |
| Total Liabilities | 50 | 83 | 108 | 120 | 163 | 204 | 262 | 445 |
| 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | |
| Capital Work in Progress | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | |
| 3 | 10 | 12 | 16 | 22 | 31 | 50 | 60 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 79 | 103 | |
| Cash & Bank | 12 | 3 | 5 | 10 | 17 | 19 | 29 | 147 |
| 20 | 38 | 46 | 50 | 68 | 91 | 40 | 47 | |
| Total Assets | 50 | 83 | 108 | 120 | 163 | 204 | 262 | 445 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 17 | 0 | 8 | 19 | 30 | 23 | 31 | 36 | |
| Cash from Investing | -11 | -21 | -15 | -6 | -22 | -19 | -14 | -36 |
| Cash from Financing | 5 | 12 | 9 | -8 | -1 | -2 | -7 | 118 |
| 12 | -9 | 2 | 5 | 7 | 2 | 9 | 118 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - Beta Drugs Limited has informed the Exchange about Copy of Newspaper Publication
2026-09-05 - Beta Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
2026-09-03 - Beta Drugs Limited has informed the Exchange about 'Beta Drugs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 24-Sep-2026 to 30-Sep-2026 for the purpose of ANNUAL GENERAL MEETING to be held on 30.09.2026
2026-09-03 - Beta Drugs Limited has informed the Exchange regarding Notice of undefined to be held on September 30, 2026
2026-09-03 - Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
2026-08-18 - Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 18, 2026.
2026-08-14 - Monitoring Agency Report for the Quarter ended 30th June, 2026
2026-07-27 - Beta Drugs Limited has informed the Exchange about Investor Presentation
2026-07-23 - The Exchange had sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
News
Recent coverage and analyst commentary for BETA
Loading news…
AI Stock Analyst
Beta Drugs Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account